Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03919292

Title field or adapter rule

{'original_value': 'Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.761696+00:00

Published At

2026-10-21T00:00:00+00:00

Record Updated At

2026-10-21

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Solid Tumor, Adult"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-21", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT03919292"

protocolSection.identificationModule.officialTitle

"Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers"

protocolSection.statusModule.overallStatus

"SUSPENDED"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Solid Tumor, Adult (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Colon', 'Glioblastoma (GBM)', 'Neratinib + Divalproex Sodium - Dose Escalation Cohort', 'Ocular Melanoma (OM)', 'Other Cancer', 'Pancreatic Cancer'], 'description': 'Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.', 'name': 'Neratinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Colon', 'Glioblastoma (GBM)', 'Neratinib + Divalproex Sodium - Dose Escalation Cohort', 'Ocular Melanoma (OM)', 'Other Cancer', 'Pancreatic Cancer'], 'description': 'Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).', 'name': 'Divalproex Sodium', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Neratinib (protocolSection.armsInterventionsModule.interventions[].name)
• Divalproex Sodium (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.